Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095719 · ClinicalTrials.gov registry record · Phase 3

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 3
Development phase
125
Enrollment target
14
Study locations

NCT00095719 is a Phase 3 study of Dementia and Alzheimers Disease that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 125 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095719, a Phase 3 study of Dementia and Alzheimers Disease, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 3
Development phase
125 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.

Conditions Studied

Dementia Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG Aripiprazole

Study Locations (14)

Florida

  • Local Institution - Hialeah
  • Local Institution - Miami
  • Local Institution - North Miami

New York

  • Local Institution - New York
  • Local Institution - Staten Island

Oklahoma

  • Local Institution - Oklahoma City
  • Local Institution - Tulsa

California

  • Local Institution - Santa Ana

Connecticut

  • Local Institution - Hamden

Indiana

  • Local Institution - Indianapolis

Ohio

  • Local Institution - Dayton

Pennsylvania

  • Local Institution - Hershey

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2003-12
Est. Completion 2005-03
Phase Phase 3

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00095719

The ClinicalTrials.gov registry entry for NCT00095719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00095719 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT00095719 about?

NCT00095719 is a clinical study titled "Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia". The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.

What is the current status of trial NCT00095719?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2003-12. Estimated completion is 2005-03.

What conditions does trial NCT00095719 study?

This clinical trial studies the following conditions: Dementia, Alzheimers Disease.

What interventions are being tested in trial NCT00095719?

The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00095719?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00095719 being conducted?

This trial has 14 study locations across California, Connecticut, Florida, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dementia

All registered trials for this condition

Alzheimers Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.